$340.81 Million in Sales Expected for United Therapeutics Co. (NASDAQ:UTHR) This Quarter

Wall Street brokerages expect that United Therapeutics Co. (NASDAQ:UTHR) will post sales of $340.81 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for United Therapeutics’ earnings, with estimates ranging from $328.00 million to $349.30 million. United Therapeutics posted sales of $373.60 million in the same quarter last year, which would indicate a negative year over year growth rate of 8.8%. The company is expected to announce its next earnings results on Wednesday, July 29th.

On average, analysts expect that United Therapeutics will report full-year sales of $1.38 billion for the current financial year, with estimates ranging from $1.35 billion to $1.40 billion. For the next year, analysts anticipate that the company will report sales of $1.39 billion, with estimates ranging from $1.22 billion to $1.47 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for United Therapeutics.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.43 by $0.69. United Therapeutics had a return on equity of 19.19% and a net margin of 36.59%. The company had revenue of $356.30 million for the quarter, compared to the consensus estimate of $343.68 million. During the same quarter in the prior year, the business earned $3.58 EPS. United Therapeutics’s revenue was down 1.7% on a year-over-year basis.

A number of research analysts recently issued reports on UTHR shares. Zacks Investment Research upgraded United Therapeutics from a “hold” rating to a “buy” rating and set a $128.00 price target on the stock in a research note on Sunday, May 3rd. Wedbush restated a “buy” rating and set a $243.00 price target on shares of United Therapeutics in a research note on Thursday, June 25th. Credit Suisse Group raised their price target on United Therapeutics from $129.00 to $145.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Oppenheimer started coverage on United Therapeutics in a research note on Wednesday, June 24th. They set a “buy” rating and a $155.00 price target on the stock. Finally, BidaskClub raised United Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, June 24th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $137.00.

Shares of UTHR traded down $0.27 during mid-day trading on Friday, reaching $119.96. The company’s stock had a trading volume of 5,788 shares, compared to its average volume of 650,721. The company’s 50 day moving average is $118.80 and its 200 day moving average is $102.01. The stock has a market cap of $5.27 billion, a PE ratio of 10.01 and a beta of 0.87. The company has a debt-to-equity ratio of 0.27, a current ratio of 8.91 and a quick ratio of 8.46. United Therapeutics has a 12-month low of $74.31 and a 12-month high of $127.79.

In other news, Director Richard Giltner sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $99.00, for a total value of $495,000.00. Following the completion of the sale, the director now directly owns 8,750 shares of the company’s stock, valued at approximately $866,250. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Tommy G. Thompson sold 3,100 shares of the firm’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $112.56, for a total value of $348,936.00. Following the completion of the transaction, the director now directly owns 9,050 shares of the company’s stock, valued at $1,018,668. The disclosure for this sale can be found here. Insiders sold a total of 207,610 shares of company stock valued at $24,546,906 over the last three months. Insiders own 10.90% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its position in shares of United Therapeutics by 10.3% during the fourth quarter. Renaissance Technologies LLC now owns 3,544,433 shares of the biotechnology company’s stock worth $312,194,000 after buying an additional 332,155 shares during the period. State Street Corp lifted its position in United Therapeutics by 1.1% in the first quarter. State Street Corp now owns 1,916,532 shares of the biotechnology company’s stock worth $181,735,000 after purchasing an additional 21,707 shares during the period. AQR Capital Management LLC lifted its position in United Therapeutics by 30.3% in the first quarter. AQR Capital Management LLC now owns 874,306 shares of the biotechnology company’s stock worth $82,906,000 after purchasing an additional 203,177 shares during the period. Nuveen Asset Management LLC lifted its position in United Therapeutics by 48.9% in the first quarter. Nuveen Asset Management LLC now owns 776,413 shares of the biotechnology company’s stock worth $73,624,000 after purchasing an additional 255,101 shares during the period. Finally, APG Asset Management N.V. acquired a new stake in United Therapeutics in the first quarter worth approximately $80,654,000. 98.11% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Recommended Story: How prevalent are 12b-1 fees?

Get a free copy of the Zacks research report on United Therapeutics (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.